Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Building genetic assessments into how we determine prognosis of ALL

David Marks • 24 Jun 2017
EHA 2017
Acute Lymphoblastic Leukemia

David Marks, MD, PhD, from the University Hospitals Bristol NHS Foundation Trust, Bristol, UK, talks to us about the need to add genetic assessments into determining the prognosis of acute lymphoblastic leukemia (ALL) patients. This was recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from David Marks

1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023

Related Videos

4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
5:14
Is transplantation and chemotherapy still necessary for all patients with Ph+ ALL?
Robin Foà • 15 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals